|Biotech partner:||SynCo Bio Partners (the Netherlands) OncoMed Pharmaceuticals (USA)|
|Type of agreement:||* manufacturing
|Nature of the agreement:||SynCo Bio Partners has expanded its current agreement with OncoMed Pharmaceuticals, a company developing novel therapeutics that target cancer stem cells.
Under the expanded agreement, in addition to antibody OMP-21M18 (anti-DLL4 antibody), SynCo will fill batches of OncoMed’s investigational products, two additional antibodies in the OncoMed pipeline for use in Phase I and II clinical trials.
SynCo will fill the OncoMed antibodies at its Amsterdam-based facility.